Evidence map›Paper›PMID 37874334›Full record

ReviewUrologie (Heidelberg, Germany)2024

[Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review].

Jakob Klemm, Markus von Deimling, Margit Fisch, Gero Kramer, Derya Tilki, Thomas Steuber, Gunhild von Amsberg, Christian Hengstenberg, Shahrokh F Shariat

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Urologie (Heidelberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Jakob KlemmKlinik für Urologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland. jakob.klemm@gmx.net.
Markus von DeimlingKlinik für Urologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.
Margit FischKlinik für Urologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.
Gero KramerKlinik für Urologie, Comprehensive Cancer Center, Medizinische Universität Wien, Wien, Österreich.
Derya TilkiKlinik für Urologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.
Thomas SteuberKlinik für Urologie, Martini-Klinik Prostatakarzinom-Zentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
Gunhild von AmsbergKlinik für Urologie, Martini-Klinik Prostatakarzinom-Zentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
Christian HengstenbergII. Univeristätsklinik für Innere Medizin, Klinik für Kardiologie, Medizinische Universität Wien, Wien, Österreich.
Shahrokh F ShariatKlinik für Urologie, Comprehensive Cancer Center, Medizinische Universität Wien, Wien, Österreich.
Universität Hamburg · DEMedical University of Vienna · ATUniversity Medical Center Hamburg-Eppendorf · DEKlinik und Poliklinik für Urologie · DEMartini-Klinik · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is the most common malignancy in men, mostly affecting older men who harbor an increased prevalence of cardiovascular disease and metabolic syndrome. Androgen deprivation therapy (ADT), the standard therapy for various stages of prostate cancer, further increases the risk for cardiovascular disease and for metabolic syndrome. Therefore, screening for cardiovascular risk factors should be performed prior to the initiation of ADT, and, if necessary, cardiological evaluation and interdisciplinary management should be provided during and after completion of ADT. Moreover, the use of a gonadotropin-releasing hormone (GnRH) antagonist may help reduce cardiovascular risk in patients with cardiovascular disease.

Indexed as

Cardiovascular DiseasesMetabolic SyndromeProstatic NeoplasmsAgedAndrogen AntagonistsAndrogensGonadotropin-Releasing HormoneHumansMaleAndrogen AntagonistsAndrogensGonadotropin-Releasing HormoneAndrogen deprivation therapyCardiovascular morbidityGonadotropin-releasing hormone-AgonistGonadotropin-releasing hormone-AntagonistProstate neoplasms

Identifiers

PMID37874334
OpenAlexW4387893056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.